The latanoprost market was valued at $1.3 billion in 2023, and is projected to reach $1.6 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.
Latanoprost is a medication primarily used in the treatment of glaucoma and ocular hypertension. It is classified as a prostaglandin analog, and works by increasing the outflow of fluid from the eye, which helps to lower intraocular pressure. Latanoprost is often prescribed to reduce the risk of damage to the optic nerve, a common complication of glaucoma, which can lead to vision loss if left untreated.
Increase in number of individuals diagnosed with glaucoma and ocular hypertension globally drives the growth of the latanoprost market. As these conditions are leading causes of vision loss, their rising prevalence fuels the market growth. As per a 2023 study published by the National Institutes of Health, approximately 70 million individuals are suffering from glaucoma worldwide.
In addition, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as the global population ages, the incidence of age-related eye conditions is expected to rise. Older adults are more likely to experience increased intraocular pressure, which directly boosts the demand for medications like latanoprost.
Moreover, rise in awareness about eye health and the importance of regular eye check-ups among both patients and healthcare providers contributes to earlier detection and treatment of glaucoma, leading to higher latanoprost market adoption. Furthermore, the availability of generic latanoprost products at a lower cost has expanded the treatment options for patients, driving the growth of the market by increasing affordability and access to the drug. However, side effects and adverse reactions associated with latanoprost such as eye irritation, changes in eye color, and potential systemic effects hamper the market growth.
In addition, availability of alternative medications for glaucoma, such as other prostaglandin analogs (e.g., travoprost and bimatoprost) or non-prostaglandin therapies, significantly restrains the market growth. On the contrary, ongoing advancements in ophthalmic drug formulations and delivery systems improve the effectiveness of treatments like latanoprost, making it a more attractive option for patients. Innovations, such as sustained-release formulations, enhance patient compliance and are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global latanoprost market size is segmented into type, indication, distribution channel, and region. On the basis type, the market is bifurcated into branded drug and generic drug. Depending on indication, it is segregated into open angle glaucoma and ocular hypertension. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of indication, the open-angle glaucoma segment is anticipated to exhibit highest growth during the forecast period.
Depending on distribution channel, the retail pharmacies segment is projected to grow at a notable pace throughout the forecast period.
Region wise, North America is likely to emerge as the most lucrative market for latanoprost in the coming years.
Latanoprost is a medication primarily used in the treatment of glaucoma and ocular hypertension. It is classified as a prostaglandin analog, and works by increasing the outflow of fluid from the eye, which helps to lower intraocular pressure. Latanoprost is often prescribed to reduce the risk of damage to the optic nerve, a common complication of glaucoma, which can lead to vision loss if left untreated.
Increase in number of individuals diagnosed with glaucoma and ocular hypertension globally drives the growth of the latanoprost market. As these conditions are leading causes of vision loss, their rising prevalence fuels the market growth. As per a 2023 study published by the National Institutes of Health, approximately 70 million individuals are suffering from glaucoma worldwide.
In addition, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as the global population ages, the incidence of age-related eye conditions is expected to rise. Older adults are more likely to experience increased intraocular pressure, which directly boosts the demand for medications like latanoprost.
Moreover, rise in awareness about eye health and the importance of regular eye check-ups among both patients and healthcare providers contributes to earlier detection and treatment of glaucoma, leading to higher latanoprost market adoption. Furthermore, the availability of generic latanoprost products at a lower cost has expanded the treatment options for patients, driving the growth of the market by increasing affordability and access to the drug. However, side effects and adverse reactions associated with latanoprost such as eye irritation, changes in eye color, and potential systemic effects hamper the market growth.
In addition, availability of alternative medications for glaucoma, such as other prostaglandin analogs (e.g., travoprost and bimatoprost) or non-prostaglandin therapies, significantly restrains the market growth. On the contrary, ongoing advancements in ophthalmic drug formulations and delivery systems improve the effectiveness of treatments like latanoprost, making it a more attractive option for patients. Innovations, such as sustained-release formulations, enhance patient compliance and are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global latanoprost market size is segmented into type, indication, distribution channel, and region. On the basis type, the market is bifurcated into branded drug and generic drug. Depending on indication, it is segregated into open angle glaucoma and ocular hypertension. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By type, the branded drug segment is expected to dominate the market from 2024 to 2033.On the basis of indication, the open-angle glaucoma segment is anticipated to exhibit highest growth during the forecast period.
Depending on distribution channel, the retail pharmacies segment is projected to grow at a notable pace throughout the forecast period.
Region wise, North America is likely to emerge as the most lucrative market for latanoprost in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global latanoprost market include Pfizer Inc., Thea Pharma Inc., Sun Pharmaceutical Industries Limited, Alcon, Taj Pharmaceuticals Limited, Viatris Inc., Apotex Inc., Wellona Pharma, Santen Pharmaceutical Co., Ltd., and Somerset Pharma LLC. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Type
- Branded Drug
- Generic Drug
By Indication
- Open Angle Glaucoma
- Ocular Hypertension
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- Thea Pharma Inc.
- Sun Pharmaceutical Industries Limited
- Alcon
- Taj Pharmaceuticals Limited
- Viatris Inc.
- Apotex Inc.
- Wellona Pharma
- Santen Pharmaceutical Co., Ltd.
- Somerset Pharma LLC
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: LATANOPROST MARKET, BY TYPE
CHAPTER 5: LATANOPROST MARKET, BY INDICATION
CHAPTER 6: LATANOPROST MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: LATANOPROST MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Pfizer Inc.
- Thea Pharma Inc.
- Sun Pharmaceutical Industries Limited
- Alcon
- Taj Pharmaceuticals Limited
- Viatris Inc.
- Apotex Inc.
- Wellona Pharma
- Santen Pharmaceutical Co., Ltd.
- Somerset Pharma LLC
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 240 |
| Published | November 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 1.3 billion |
| Forecasted Market Value ( USD | $ 1.6 billion |
| Compound Annual Growth Rate | 2.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
